 Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial of the companys selective oral DHODH inhibitor, IMU-838, for the treatment of patients with coronavirus disease 2019 COVID-19. The IONIC trial is a prospective, randomized, parallel-group, open-label phase 2b study, designed to evaluate efficacy and safety of IMU-838 in combination with the neuraminidase inhibitor, Oseltamivir Tamiflu, in approximately 120 adult patients with moderate-to-severe COVID-19. 